Lumbrokinase (Earthworm) and stroke

What 3 graded rows on lumbrokinase (earthworm) agree on for stroke, and where they differ. Counted side by side, never averaged.

What the rows agree on

Each block and row is one graded row from the Lumbrokinase (Earthworm) page, with its PubMed record.

Your question

Supplement
Lumbrokinase (Earthworm) Choose another

Lumbrokinase (Earthworm) and stroke

3 rows · 541 people

They agree: all 3 rows found an improvement.

No difference
Improved
Each block is one evidence row, sized by how many people it enrolled, with its grade inside.
  • Grade D× 3
Rows
3
Trials
3
People
541

What the rows share

From the rows

The best-graded row, grade D, is a randomized trial of 310 people (2013) and found an improvement.

The rows run from 51 to 310 people, published from 2000 to 2021: 3 single studies.

The rows

3 improved
  1. Grade DVascular events over 1 year after ischemic stroke · Improved

    RCT · n 310 · 2013 · Hospitalized ischemic stroke patients (192 lumbrokinase, 118 control), all on standard stroke treatment

    Oral capsules (dose not stated in the abstract) · 12 months

    Total vascular events were 2.08% vs 6.78% and cerebral vascular events 1.04% vs 5.93% (P < 0.05); fibrinogen, carotid wall thickness and plaque measures also favored lumbrokinase.

    Row on the Lumbrokinase (Earthworm) page · PubMed 24229674 (opens PubMed)

  2. Grade DStroke disability scores (NIHSS, Barthel Index) at 30 days · Improved

    RCT · n 180 · 2021 · Adults with acute ischemic stroke at an Indonesian referral centre, all on aspirin 100 mg, atorvastatin and vitamin B12

    Three times daily (amount not stated in the abstract) · 30 days

    NIHSS improved more with DLBS1033 at discharge (−5.57 vs −3.64) and day 30 (−6.62 vs −5.14), as did Barthel Index scores; good functional outcome (mRS <2) at day 30 did not differ significantly (86.7% vs 80%). No clinically significant product-related adverse events.

    Row on the Lumbrokinase (Earthworm) page · PubMed 33927846 (opens PubMed)

  3. Grade DStroke scores and clotting markers in cerebral infarction · Improved

    RCT · n 51 · 2000 · Patients with cerebral infarction (31 lumbrokinase, 20 control)

    Not stated in the abstract · Not stated in the abstract

    Stroke scores fell in both groups, more with lumbrokinase; KPTT lengthened, t-PA activity and D-dimer rose and fibrinogen fell, while PT and PAI did not change.

    Row on the Lumbrokinase (Earthworm) page · PubMed 11321442 (opens PubMed)

Educational only. Not medical advice. Some links earn us a commission: kymatahealth.com/affiliate-disclosure.